Summary The International Myeloma Working Group consensus aimed to provide
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …

Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people
each year and is the second most common hematologic malignancy. It is part of a spectrum …

Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

We have studied a three-drug combination with cyclophosphamide, bortezomib and
dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple …

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …

Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple
myeloma. We treated patients with light chain amyloidosis (AL) before stem cell …

This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of
pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in patients with …

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple
Myeloma Page 1 Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for …